Literature DB >> 28274669

Response to: Comparison of infliximab drug measurement across three commercially available ELISA kits.

D Nagore1, N Rapún2, I Antón2, J Harper3, A Martínez4.   

Abstract

Mesh:

Substances:

Year:  2017        PMID: 28274669     DOI: 10.1016/j.pathol.2017.01.004

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


× No keyword cloud information.
  1 in total

1.  Verification between Original and Biosimilar Therapeutic Antibody Infliximab Using nSMOL Coupled LC-MS Bioanalysis in Human Serum.

Authors:  Noriko Iwamoto; Kotoko Yokoyama; Megumi Takanashi; Atsushi Yonezawa; Kazuo Matsubara; Takashi Shimada
Journal:  Curr Pharm Biotechnol       Date:  2018       Impact factor: 2.837

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.